ArticleCancer informatics2026
C1QBP Associated With Immune Infiltration Predicts Poor Prognosis in Lung Adenocarcinoma.
Article in Cancer informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: C1QBP is a multi-compartmental protein implicated in diverse cellular processes. However, its clinical predictive value, particularly its association with immune cell infiltration, in lung adenocarcinoma (LUAD) remains unelucidated. Thus, the present study aimed to comprehensively evaluate C1QBP expression patterns, prognostic significance, and its correlation with the tumor immune microenvironment (TIME) in LUAD. Methods: We first assessed C1QBP expression levels and prognostic relevance in LUAD using multiple bioinformatics platforms. Subsequently, we analyzed the associations of C1QBP expression with immune cell infiltration and immunotherapeutic response, and identified signaling pathways linked to C1QBP expression via Gene Set Enrichment Analysis (GSEA). Finally, enzyme-linked immunosorbent assay (ELISA) was employed to validate the correlation between serum C1QBP concentration and prognosis in non-small cell lung cancer (NSCLC) patients receiving immunotherapy. Results: C1QBP was highly expressed in LUAD tissues, and this high expression was significantly associated with advanced tumor stage. Moreover, high C1QBP expression emerged as an independent risk factor for overall survival (OS) in LUAD patients. Bioinformatics analyses revealed that C1QBP expression was negatively correlated with the infiltration levels of multiple immune cell subsets (including T cells, B cells, and dendritic cells) in LUAD, while patients with low C1QBP expression exhibited higher Immunophenoscore (IPS). GSEA further demonstrated that high C1QBP expression was positively correlated with pathways regulating the tumor cell cycle, but negatively correlated with immune-related signaling pathways. Finally, in NSCLC patients treated with immune checkpoint inhibitors (ICIs), those with higher serum C1QBP concentrations had significantly shorter OS and progression-free survival (PFS). Conclusions: Our study identifies C1QBP as a potential oncogene that is closely associated with the TIME in LUAD. Collectively, these findings suggest that C1QBP holds promise as a novel indicator of poor prognosis in LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.